1(self.webpackChunk_N_E=self.webpackChunk_N_E||[]).push([[333],{705:(e,t,a)=>{"use strict";Object.defineProperty(t,"__esModule",{value:!0});var i={default:function(){return c},noSSR:function(){return o}};for(var s in i)Object.defineProperty(t,s,{enumerable:!0,get:i[s]});let l=a(4252);a(7876),a(4232);let n=l._(a(6006));function r(e){return{default:e?.default||e}}function o(e,t){return delete t.webpack,delete t.modules,e(t)}function c(e,t){let a=n.default,i={loading:({error:e,isLoading:t,pastDelay:a})=>null};e instanceof Promise?i.loader=()=>e:"function"==typeof e?i.loader=e:"object"==typeof e&&(i={...i,...e});let s=(i={...i,...t}).loader;return(i.loadableGenerated&&(i={...i,...i.loadableGenerated},delete i.loadableGenerated),"boolean"!=typeof i.ssr||i.ssr)?a({...i,loader:()=>null!=s?s().then(r):Promise.resolve(r(()=>null))}):(delete i.webpack,delete i.modules,o(a,i))}("function"==typeof t.default||"object"==typeof t.default&&null!==t.default)&&void 0===t.default.__esModule&&(Object.defineProperty(t.default,"__esModule",{value:!0}),Object.assign(t.default,t),e.exports=t.default)},1072:(e,t,a)=>{(window.__NEXT_P=window.__NEXT_P||[]).push(["/study/[pid]",function(){return a(8211)}])},1327:(e,t,a)=>{"use strict";a.d(t,{$H:()=>n,Ow:()=>s,j4:()=>l});var i=a(104);let s=async e=>{try{let t=await fetch(i.searchUrl,{headers:{accept:"application/json, text/plain, */*","accept-language":"en-US,en;q=0.9","content-type":"application/json;charset=UTF-8"},body:JSON.stringify(e),method:"POST",mode:"cors",credentials:"omit"}),a=await t.json();return{tag:"Value",value:a}}catch(e){return{tag:"Error",error:{message:e.message||"Server request error",code:e.statusCode}}}},l=async(e,t=fetch)=>{try{let a=await t(e||i.allTrialsIds),s=await a.json();return{tag:"Value",value:s}}catch(e){return{tag:"Error",error:{message:e.message||"Server request error",code:e.statusCode}}}},n=async e=>{try{let t=await fetch((0,i.studyResultByUniqueStudyId)(e),{headers:{accept:"text/html, text/plain, */*","accept-language":"en-US,en;q=0.9","content-type":"text/html;charset=UTF-8"},method:"GET",mode:"cors",credentials:"omit"}),a=await t.text();return{tag:"Value",value:a}}catch(e){return{tag:"Error",error:{message:e.message||"Server request error",code:e.statusCode}}}}},2936:(e,t,a)=>{"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"LoadableContext",{enumerable:!0,get:function(){return i}});let i=a(4252)._(a(4232)).default.createContext(null)},3505:(e,t,a)=>{"use strict";a.d(t,{JL:()=>i,V9:()=>l,Yq:()=>r,h3:()=>n});let i=(e,t,a,i,l)=>null!=a&&null!=t&&e.length>0?(e.forEach(e=>{void 0!==e&&(e.distance=s(e.Latitude,e.Longitude,t,a))}),e&&e.length>1&&(e=e.filter(e=>{if(e&&(0===e.distance||e.distance))return e.distance<=+l})).sort((e,t)=>e.distance&&t.distance?e.distance-t.distance:0),e.length>1&&e[0].distance===e[1].distance&&e[0].Name!==i&&null!==e[0].Name&&null!=i&&""!==i&&(Array.prototype.swap=function(e,t){var a=this[e];this[e]=this[t],this[t]=a},e.swap(0,e.findIndex(({Name:e})=>e===`${i}`))),e.filter(e=>!!e)):e,s=(e,t,a,i)=>{let s=e=>parseFloat(e)*Math.PI/180,l=Math.sin(s(a))*Math.sin(s(e))+Math.cos(s(a))*Math.cos(s(e))*Math.cos(s(t)-s(i));return 3959*Math.acos(parseFloat(l.toFixed(8)))},l=(e,t,a)=>{if(!a.getBounds())return console.log("map.getBounds() not working"),[];let i=a.getBounds();return e.filter(e=>{if(!e.Latitude||!e.Longitude)return!1;let t=parseFloat(e.Latitude),a=parseFloat(e.Longitude);return t>
1=i.getSouthWest().lat()-1e-9&&t<=i.getNorthEast().lat()+1e-9&&a>=i.getSouthWest().lng()-1e-9&&a<=i.getNorthEast().lng()+1e-9})},n=e=>{let t=new google.maps.LatLngBounds;return e.forEach(e=>{if(e){let a=new google.maps.LatLng(parseFloat(e.Latitude),parseFloat(e.Longitude));t.extend(a)}}),t},r=(e,t,a,i,s,l,n,r,o)=>{e.forEach(e=>{if(e&&e.Latitude&&e.Longitude){let c=`${1e4*parseFloat(e.Latitude)}_${1e4*parseFloat(e.Longitude)}`;void 0===a[c]&&(a[c]=[]),a[c].push(e);let d=Object.assign(new google.maps.Marker({position:new google.maps.LatLng(parseFloat(e.Latitude),parseFloat(e.Longitude)),title:i?e.Name:`${e.StudyId} - Study Location Details`,draggable:!1,icon:r?o?{url:r,scaledSize:new google.maps.Size(o.width,o.height),anchor:new google.maps.Point(20,40),origin:new google.maps.Point(0,0)}:{url:r}:void 0}),{markersClusterKey:c,lat:e.Latitude,long:e.Longitude});d.setMap(s),d.addListener("click",()=>n(d)),l.current.includes(c)||(l.current.push(c),t.push(d))}})}},6006:(e,t,a)=>{"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return m}});let i=a(4252)._(a(4232)),s=a(2936),l=[],n=[],r=!1;function o(e){let t=e(),a={loading:!0,loaded:null,error:null};return a.promise=t.then(e=>(a.loading=!1,a.loaded=e,e)).catch(e=>{throw a.loading=!1,a.error=e,e}),a}class c{constructor(e,t){this._loadFn=e,this._opts=t,this._callbacks=new Set,this._delay=null,this._timeout=null,this.retry()}promise(){return this._res.promise}retry(){this._clearTimeouts(),this._res=this._loadFn(this._opts.loader),this._state={pastDelay:!1,timedOut:!1};let{_res:e,_opts:t}=this;e.loading&&("number"==typeof t.delay&&(0===t.delay?this._state.pastDelay=!0:this._delay=setTimeout(()=>{this._update({pastDelay:!0})},t.delay)),"number"==typeof t.timeout&&(this._timeout=setTimeout(()=>{this._update({timedOut:!0})},t.timeout))),this._res.promise.then(()=>{this._update({}),this._clearTimeouts()}).catch(e=>{this._update({}),this._clearTimeouts()}),this._update({})}_update(e){this._state={...this._state,error:this._res.error,loaded:this._res.loaded,loading:this._res.loading,...e},this._callbacks.forEach(e=>e())}_clearTimeouts(){clearTimeout(this._delay),clearTimeout(this._timeout)}getCurrentValue(){return this._state}subscribe(e){return this._callbacks.add(e),()=>{this._callbacks.delete(e)}}}function d(e){return function(e,t){let a=Object.assign({loader:null,loading:null,delay:200,timeout:null,webpack:null,modules:null},t),l=null;function o(){if(!l){let t=new c(e,a);l={getCurrentValue:t.getCurrentValue.bind(t),subscribe:t.subscribe.bind(t),retry:t.retry.bind(t),promise:t.promise.bind(t)}}return l.promise()}if(!r){let e=a.webpack&&1?a.webpack():a.modules;e&&n.push(t=>{for(let a of e)if(t.includes(a))return o()})}function d(e,t){let n;o(),(n=i.default.useContext(s.LoadableContext))&&Array.isArray(a.modules)&&a.modules.forEach(e=>{n(e)});let r=i.default.useSyncExternalStore(l.subscribe,l.getCurrentValue,l.getCurrentValue);return i.default.useImperativeHandle(t,()=>({retry:l.retry}),[]),i.default.useMemo(()=>{var t;return r.loading||r.error?i.default.createElement(a.loading,{isLoading:r.loading,pastDelay:r.pastDelay,timedOut:r.timedOut,error:r.error,retry:l.retry}):r.loaded?i.default.createElement((t=r.loaded)&&t.default?t.default:t,e):null},[e,r])}return d.preload=()=>o(),d.displayName="LoadableComponent",i.default.forwardRef(d)}(o,e)}function u(e,t){let a=[];for(;e.length;){let i=e.pop();a.push(i(t))}return Promise.all(a).then(()=>{if(e.length)return u(e,t)})}d.preloadAll=()=>new Promise((e,t)=>{u(l).then(e,t)}),d.preloadReady=(e=[])=>new Promise(t=>{let a=()=>(r=!0,t());u(n,e).then(a,a)}),window.__NEXT_PRELOADREADY=d.preloadReady;let m=d},8211:(e,t,a)=>{"use strict";a.r(t),a.d(t,{__N_SSG:()=>el,default:()=>en});var i,s=a(7876),l=a(9880),n=a(4982),r=a(104),o=a(6952),c=a(5277),d=a(4232),u=a(8230),m=a.n(u),p=a(9099),h=a(4543),f=a(2051),b=a(9149),x=a(2328),y=a(5388),g=a(2677);let w=({returnBtn:e=!1,pageData:t})=>{let[a,i]=(0,d.useState)("");(0,d.useEffect)(()=>{window.scrollTo(0,0),i(location.href)},[]);let{searchState:l}=(0,g.A)(),n=(0,p.useRouter)(),r="string"==typeof n.query.page&&n.query.page||"0",o=(0,y.Ue)(l);return o+=`&page=${r}`,(0,s.jsx)(h.Y,{className:`pt-2 md:pt-6 md:pb-4 sharing ${e?"with-return":""}`,backgroundColor:"#3C4242",children:(0,s.jsxs)("div",{className:"flex justify-between w-full px-1 md:px-0 flex-col md:flex-row font-bold font-secondary italic leading-[19px] divi
1de-y divide-white md:divide-none",children:[e?(0,s.jsxs)(m(),{href:o,className:"flex items-center py-3 pr-6 mb-2 text-white md:py-0 return-btn sm:mb-0",children:[(0,s.jsx)(b.Y5o,{className:"inline-block h-5 mr-2"}),(0,s.jsx)("span",{className:"border-white border-b-2 transition-all border-opacity-0 duration-300 whitespace-nowrap",children:t.returnToLabel})]}):"",(0,s.jsxs)("div",{className:"flex flex-col justify-end divide-y divide-white md:flex-row md:divide-y-0 md:divide-x",children:[(0,s.jsxs)("div",{className:"flex flex-wrap items-center w-full py-3 pr-6 socials print:hidden md:py-0",children:[(0,s.jsx)("label",{className:"py-1",children:t.shareLabel}),(0,s.jsx)("a",{href:"https://www.facebook.com/sharer/sharer.php?u="+a,className:"inline-block ml-6 border border-opacity-50 rounded-full border-asphalt",children:(0,s.jsx)(f.FaFacebookF,{})}),(0,s.jsxs)("a",{href:"https://twitter.com/share?url="+a,className:"inline-block ml-6 border border-opacity-50 rounded-full border-asphalt",children:[(0,s.jsx)("span",{className:"hidden",children:"Twitter"}),(0,s.jsxs)("svg",{xmlns:"http://www.w3.org/2000/svg",width:"24",height:"23",viewBox:"0 0 24 23",fill:"none",style:{width:"16px",height:"16px"},children:[(0,s.jsx)("g",{clipPath:"url(#clip0_54118_2)",children:(0,s.jsx)("path",{d:"M18.9014 0.653137H22.5813L14.5415 9.84251L24 22.3468H16.5938L10.7935 14.7628L4.15636 22.3468H0.473859L9.07331 12.5179L0 0.653137H7.5937L12.837 7.58501L18.9014 0.653137ZM17.6097 20.144H19.649L6.48577 2.74034H4.29764L17.6097 20.144Z",fill:"#fff"})}),(0,s.jsx)("defs",{children:(0,s.jsx)("clipPath",{id:"clip0_54118_2",children:(0,s.jsx)("rect",{width:"24",height:"21.6937",fill:"white",transform:"translate(0 0.653137)"})})})]})]}),(0,s.jsxs)("a",{href:`mailto:?subject=Studies on AstraZeneca Trial Finder 2 &body=mailto:?subject=AstraZeneca Clinical Trials&body=${encodeURIComponent(t.emailLeadText)}%0D%0A%0D%0A${encodeURIComponent(a)}%0D%0A%0D%0A${encodeURIComponent(t.emailNote)}`,target:"_blank",className:"inline-block ml-6 border border-opacity-50 rounded-full border-asphalt",children:[(0,s.jsx)("span",{className:"hidden",children:"FaEnvelope"}),(0,s.jsx)(f.FaEnvelope,{})]}),(0,s.jsxs)("a",{href:"https://www.linkedin.com/shareArticle?mini=true&url="+a,className:"inline-block ml-6 border border-opacity-50 rounded-full border-asphalt",children:[(0,s.jsx)("span",{className:"hidden",children:"FaLinkedin"}),(0,s.jsx)(f.FaLinkedin,{})]})]}),(0,s.jsxs)("button",{className:"flex items-center py-3 cursor-pointer md:justify-between md:pl-8 md:py-0 focus:underline hover:underline print",onClick:()=>{setTimeout(()=>{window.print(),(0,x.u)("Print",{category:"Print",action:"Click",label:"Print page"})},300)},children:[(0,s.jsx)("label",{className:"pr-4 italic",children:t.printLabel}),(0,s.jsxs)("a",{className:"inline-block border border-opacity-50 rounded-full cursor-pointer border-asphalt",children:[(0,s.jsx)("span",{className:"hidden",children:"FaPrint"}),(0,s.jsx)(f.FaPrint,{})]})]})]})]})})},v=({study:e,labels:t})=>{let a=e?.secondary_ids&&e?.secondary_ids.find(e=>e.id_type?.includes("EudraCT")),i=[{label:t.studyIdentifier,value:e?.org_study_id||"N/A"},{label:t.ctGovIdentifier,...e?.nct_number?{value:e?.nct_number,href:`https://clinicaltrials.gov/study/${e?.nct_number}?rank=1`}:{value:"N/A"}},{label:t.eudraCtIdentifier,...a?{value:a.id,href:`https://www.clinicaltrialsregister.eu/ctr-search/search?query=${a.id}`}:{value:"N/A"}},{label:t.ctisCtIdentifier,...e?.ctis_id?{value:e?.ctis_id,href:"https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en"}:{value:"N/A"}}];return(0,s.jsx)(h.Y,{className:"bg-primary-claret text-white",children:(0,s.jsxs)("div",{className:"px-1 md:px-0 py-6 md:py-12 w-full flex flex-wrap",children:[(0,s.jsx)("div",{className:"w-full flex items-center md:w-9/12 md:pr-8 md:border-r border-black-200",children:(0,s.jsx)("h1",{className:"text-3.5xl md:text-5.5xl leading-[48px] md:leading-[56px] italic font-secondary text-left font-light",children:`${e?.brief_title} ${e&&e.acronym&&e.acronym.length>0&&"n/a"!==e.acronym.toLocaleLowerCase()&&"na"!==e.acronym.toLocaleLowerCase()?`- ${e.acronym}`:""}`})}),(0,s.jsx)("div",{className:"w-full md:w-3/12 md:pl-8 pt-8 md:pt-0 mt-8 md:mt-0 border-t md:border-t-0",children:i.map((e,t)=>(0,s.jsxs)("p",{className:"font-bold font-secondary italic text-base leading-[19px] pb-4 md:pb-6 last:pb-0",children:[e.label,e.href?(0,s.jsx)("a",{className:"block font-third font-light text-xl leading-8 not-italic hover:underline",href:e.href,rel:"noopener noreferrer",target:"_blank",children:e.value}):(0,s.jsx)("span",{className:"block font-third font-light text-xl not-italic leading-8",children:e.value})]},t))})]})})};var T=((i={})[i.GENERIC_ATTACHMENT=0]="GENERIC_ATTACHMENT",i[i.TRIAL_SUMMARIES=1]="TRIAL_SUMMARIES",i[i.THANK_YOU_CARD=2]="THANK_YOU_CARD",i);let D="ATTACHTYPE_THANK_YOU_CARD";var C=a(1227);let _=({attachment:e,studyNctId:t,attachmentType:a})=>{let i=e.url?(0,C.l2)(e.url):e.url,l=a===T.GENERIC_ATTACHMENT?(0,s.jsx)("div",{className:"flex flex-col",children:(0,s.jsxs)("div",{className:"flex justify-between items-center text-base",children:[(0,s.jsx)("div",{className:"flex flex-col pr-4 break-words",children:(0,s.jsx)("h4",{className:"text-lg leading-[22px] font-light break-words font-secondary text-primary-claret",children:e.description||e.url})}),(0,s.jsxs)("a",{href:i,className:"download-btn flex items-center justify-center font-secondary font-bold italic text-gray leading-[19px] transition-all duration-300 hover:underline focus:outline-none hover:text-primary-claret",target:"_blank",rel:"noopener noreferrer",onClick:()=>{(0,x.u)("DownloadAttachments",{category:"Download",action:"Click link",label:`${t}_${e.description||e.url||"N/A"}`})},children:["Download",(0,s.jsx)(b.U01,{className:"w-5 h-5 ml-[10px] text-black"})]})]})}):(0,s.jsx)(s.Fragment,{});return(0,s.jsx)(s.Fragment,{children:l})},S=({attachment:e,studyNctId:t,attachmentType:a})=>{let i=a===T.TRIAL_SUMMARIES?(0,s.jsx)("div",{className:"flex flex-col",children:(0,s.jsxs)("div",{className:"flex justify-between items-center text-base",children:[(0,s.jsx)("div",{className:"flex flex-col pr-4 break-words",children:(0,s.jsx)("h4",{className:"text-lg leading-[22px] font-light break-words font-secondary text-primary-claret",children:e.description||e.url})}),(0,s.jsxs)("a",{href:e.url,className:"download-btn flex items-center justify-center font-secondary font-bold italic text-gray leading-[19px] transition-all duration-300 hover:underline focus:outline-none hover:text-primary-claret",target:"_blank",rel:"noopener noreferrer",onClick:()=>{(0,x.u)("DownloadAttachments",{category:"Download",action:"Click link to TRS",label:`${t}_${e.description||e.url}
2 || 'N/A'}`})},children:["Available here",(0,s.jsx)(b.o4q,{className:"w-5 h-5 ml-[10px] text-black -rotate-45"})]})]})}):(0,s.jsx)(s.Fragment,{});return(0,s.jsx)(s.Fragment,{children:i})};var j=a(4774);let N=({isOpen:e,onClose:t,attachment:a,languages:i,onDownload:l})=>{let[n,r]=(0,d.useState)(i[0]||""),[o,c]=(0,d.useState)(!1);return(0,d.useEffect)(()=>{i.length>0&&r(i[0])},[i]),(0,s.jsxs)(j.A,{isOpen:e,showModal:()=>{},hideModal:t,CloseButton:b.fUT,closeButtonStyle:"absolute -m-7 hover:cursor-pointer",dialogOverlayStyle:"min-h-screen min-w-screen bg-modal-overlay p-0 fixed top-0 right-0 left-0 bottom-0 overflow-scroll z-[99999] flex items-center p-8 px-0 md:px-8",dialogContentStyle:"bg-white block max-w-6xl shadow-contact-modal w-full lg:w-1/2 mx-auto relative p-4 sm:p-8 m-0 rounded-lg text-center py-12",disableScroll:!0,children:[(0,s.jsx)("h3",{className:"text-xl font-bold mb-4 heading",children:"Available Languages"}),(0,s.jsxs)("div",{className:"relative inline-block w-full text-gray-700 mb-4",children:[(0,s.jsxs)("button",{onClick:()=>{c(!o)},className:"dropdown-btn flex items-center justify-center w-full bg-white border border-gray-400 hover:border-gray-500 px-4 py-2 rounded shadow leading-tight focus:outline-none focus:shadow-outline",children:[(0,s.jsx)("span",{className:"border-primary-pink border-b-2 transition-all border-opacity-0 duration-300 flex items-center",children:n}),(0,s.jsx)(f.FaCaretDown,{className:"inline text-base md:text-lg ml-1"})]}),o&&(0,s.jsx)("div",{className:"absolute mt-2 w-full bg-white shadow-lg z-10",children:i.map(e=>(0,s.jsx)("div",{onClick:()=>{r(e),c(!1)},className:"cursor-pointer px-4 py-2 hover:bg-gray-200 oi ",children:e},e))})]}),(0,s.jsx)("button",{onClick:()=>{n&&(l(a?.Url?.replace("{language}",n)||""),t())},className:"mt-4 bg-primary-claret text-white py-2 px-4 rounded hover:bg-primary-claret-dark focus:outline-none",children:"Download"})]})},A=({attachments:e,studyNctId:t})=>{let[a,i]=(0,d.useState)(!1),[l,n]=(0,d.useState)(null),[r,o]=(0,d.useState)([]),c=e=>e.charAt(0).toUpperCase()+e.slice(1),u=e.find(e=>{var t;return t=e,(t?.Url&&t?.Url?.includes("www.trialsummaries.com")?"ATTACHTYPE_TRIAL_SUMMARIES":t?.TypeInternal&&(t?.TypeInternal===D||t?.TypeInternal.startsWith("ATTACHTYPE_THANK_YOU_CARD"))?D:"ATTACHTYPE_GENERIC_ATTACHMENT")===D});return(0,s.jsxs)("div",{className:"flex flex-col",children:[u&&(0,s.jsxs)("div",{className:"flex justify-between items-center text-base bg-[#f6f6f6] rounded-lg",children:[(0,s.jsx)("div",{className:"flex flex-col pr-4 break-words",children:(0,s.jsx)("h4",{className:"text-lg leading-[22px] font-light break-words font-secondary text-primary-claret",children:u.TypeDisplay||u.Url})}),(0,s.jsxs)("button",{onClick:()=>{var t;let a;n(u),o((t=e,a=RegExp(`${D}_([A-Z]+)$`),t.filter(e=>e?.TypeInternal?.startsWith(D)).map(e=>{let t=e?.TypeInternal?.match(a);return t&&t[1]?c(t[1].toLowerCase()):"English"}))),i(!0)},className:"download-btn flex items-center justify-center font-secondary font-bold italic text-gray leading-[19px] transition-all duration-300 hover:underline focus:outline-none hover:text-primary-claret",children:["Download",(0,s.jsx)(b.U01,{className:"w-5 h-5 ml-[10px] text-black"})]})]}),l&&(0,s.jsx)(N,{isOpen:a,onClose:()=>i(!1),attachment:l,languages:r,onDownload:e=>{(0,x.u)("DownloadAttachments",{category:"Download",action:"Click link",label:`${t}_${e||"N/A"}`}),window.open(e,"_blank","noopener noreferrer")}})]})};function L(e){return e?.url&&e?.url?.includes("trialsummaries.com")?T.TRIAL_SUMMARIES:e?.TypeInternal&&(e?.TypeInternal===D||e?.TypeInternal.startsWith(D))?T.THANK_YOU_CARD:T.GENERIC_ATTACHMENT}let E=({attachments:e,links:t,studyNctId:a})=>{let i=[...e,...t],l=i.filter(e=>L(e)===T.THANK_YOU_CARD),n=i.filter(e=>L(e)!==T.THANK_YOU_CARD);return(0,s.jsxs)(h.Y,{className:"attachments-section bg-white px-2 md:px-0 py-12",children:[(0,s.jsx)("h2",{className:"text-[23px] leading-[29px] font-secondary font-bold text-gray text-left mb-8",children:"Documents available"}),(0,s.jsxs)("ul",{children:[n&&n.map((e,t)=>(0,s.jsx)("li",{className:"mt-6 first:mt-0 py-[26px] pl-6 pr-6 bg-[#f6f6f6]",children:function(e,t){let a=L(e);switch(a){case T.GENERIC_ATTACHMENT:return(0,s.jsx)(_,{attachment:e,studyNctId:t,attachmentType:a});case T.TRIAL_SUMMARIES:return(0,s.jsx)(S,{attachment:e,studyNctId:t,attachmentType:a});default:return(0,s.jsx)(s.Fragment,{})}}(e,a)},t)),l.length>0&&(0,s.jsx)("li",{className:"mt-6 first:mt-0 py-[26px] pl-6 pr-6 bg-[#f6f6f6]",children:(0,s.jsx)(A,{attachments:l,studyNctId:a})})]})]})};var I=a(6721),k=a(8847),R=a.n(k),P=a(3505),O=a(8696);let H=({location:e,isStatusHidden:t})=>{let{Latitude:a,Longitude:i}=(0,p.useRouter)().query;return(0,s.jsxs)("div",{className:"md:py-6 px-4 lg:px-8 w-full flex flex-wrap font-secondary items-center justify-center bg-white even:bg-[#EBEFEE] text-black border border-box md:border-transparent",children:[(0,s.jsx)("div",{className:`w-full ${t?"":"md:w-4/5"} py-4 md:py-0`,children:(0,s.jsxs)("div",{className:"flex w-full",children:[(0,s.jsx)("p",{className:"md:hidden w-1/2 md:w-full pr-2 text-black",children:"Location"}),(0,s.jsxs)("div",{className:"flex flex-col w-1/2 md:w-full",children:[(0,s.jsx)("h3",{className:"text-base text-primary-claret font-bold font-lexia italic leading-[19px]",children:e.Name}),(0,s.jsx)("p",{className:"text-xs leading-4 text-black mb-2",children:[`${e.City}`,`${e.StateDisplay}`,`${e.CountryDisplay}`,`${e.PostalCode}`].filter(e=>"null"!==e).join(", ")}),a&&i&&(0,s.jsxs)("div",{className:"flex items-center mt-2",children:[(0,s.jsx)(f.FaMapMarkerAlt,{className:"h-4 w-4 mr-2 text-[#B2B4B4]"}),(0,s.jsxs)("p",{className:"font-secondary italic text-base leading-5 text-gray",children:[(0,s.jsx)("span",{children:(0===e.distance||e.distance)&&`${Math.floor(e.distance)} miles away `}),"from your location"]})]})]})]})}),t?null:(0,s.jsx)("div",{className:"w-full md:w-1/5 py-4 md:py-0",children:(0,s.jsxs)("div",{className:"flex w-full",children:[(0,s.jsx)("p",{className:"md:hidden w-1/2 md:w-full pr-2 text-black",children:"Status"}),(0,s.jsx)("div",{className:"flex flex-col w-1/2 md:w-full",children:(0,s.jsxs)("p",{className:"flex items-center text-gray text-base font-secondary leading-5 italic font-light",children:[(()=>{switch(e.StatusDisplayInternal){case null:return;case"LOCSTATUS_RECRUITING":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-3 text-study_status-recruiting"});case"LOCSTATUS_WILL_BE_RECRUITING":case"LOCSTATUS_NOT_YET_REC":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-3 text-study_status-not_yet_recruiting"});case"LOCSTATUS_RECRUITMENT_COMPLETE":case"LOCSTATUS_COMPLETED":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-3 text-study_status-recruiting_complete"});case"LOCSTATUS_STUDY_COMPLETE":case"LOCSTATUS_STUDY_COMPLETED":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-3 text-study_status-completed"});default:return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-3 text-study_status-other"})}})(),(0,s.jsx)("span",{children:e.StatusDisplay})]})})]})})]})};var M=a(1025);let $=({locations:e,internalStatus:t,hideStatus:a=!1})=>{let i=["RECSTATUS_COMPLETED","RECSTATUS_STUDY_COMPLETED","RECSTATUS_RECRUITMENT_ON_HOLD","RECSTATUS_TERMINATED","RECSTATUS_OTHER","RECSTATUS_NOT_YET_REC"].includes(t)||a,[l,n]=(0,d.useState)(e),[r,o]=(0,d.useState)(0),[c,u]=(0,d.useState)(0),{width:m}=(0,M.A)(),p=(0,d.useRef)(null);return(0,d.useEffect)(()=>{o(0),u(0)},[e]),(0,d.useEffect)(()=>{let t=r+8;n(e.slice(r,t))},[r,8,e]),(0,s.jsxs)("div",{className:"flex flex-col locations-container",ref:p,id:"locations",children:[(0,s.jsxs)("div",{className:"py-4 px-8 mt-6 w-full hidden md:flex items-center justify-center italic font-secondary border-b border-black-100 text-black-default text-base leading-5",children:[(0,s.jsx)("div",{className:`${i?"w-full":"w-4/5"}`,children:(0,s.jsx)("p",{children:"Location"})}),i?null:(0,s.jsx)("div",{className:"w-1/5",children:(0,s.jsx)("p",{children:"Status"})})]}),(0,s.jsx)("div",{className:"list-container overflow-auto mt-4 md:mt-0",children:l.map((e,t)=>(0,s.jsx)(H,{isStatusHidden:i,location:e},t))}),e.length>8&&(0,s.jsx)(O.d,{className:"light mt-4 mx-auto",totalItems:e.length,itemsPerPage:8,onChange:t=>{o(8*t.selected%e.length),u(t.selected),m&&m<768&&p&&p.current&&p.current.scrollIntoView({behavior:"smooth"})},page:c})]})},U=e=>{switch(e){case null:return;case"LOCSTATUS_RECRUITING":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-2 text-study_status-recruiting"});case"LOCSTATUS_WILL_BE_RECRUITING":case"LOCSTATUS_NOT_YET_REC":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-2 text-study_status-not_yet_recruiting"});case"LOCSTATUS_RECRUITMENT_COMPLETE":case"LOCSTATUS_COMPLETED":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-2 text-study_status-recruiting_complete"});case"LOCSTATUS_STUDY_COMPLETE":case"LOCSTATUS_STUDY_COMPLETED":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-2 text-study_status-completed"});default:return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-2 text-study_status-other"})}},F=({activeOption:e,setActiveOption:t,labels:a})=>{let i=(0,d.useRef)(null),[l,n]=(0,d.useState)(!1),r=[{InternalValue:null,AvailableStatuses:[],DisplayValue:a.locationSortByStatusLabels.defaultValue},{InternalValue:"LOCSTATUS_RECRUITING",AvailableStatuses:["LOCSTATUS_RECRUITING"],DisplayValue:a.locationSortByStatusLabels.recruitingLabel},{InternalValue:"LOCSTATUS_NOT_YET_REC",AvailableStatuses:["LOCSTATUS_NOT_YET_REC","LOCSTATUS_WILL_BE_RECRUITING"],DisplayValue:a.locationSortByStatusLabels.notYetRecruitingLabel},{InternalValue:"LOCSTATUS_STUDY_COMPLETED",AvailableStatuses:["LOCSTATUS_STUDY_COMPLETED","LOCSTATUS_STUDY_COMPLETE"],DisplayValue:a.locationSortByStatusLabels.recruiting
2CompleteLabel},{InternalValue:"LOCSTATUS_COMPLETED",AvailableStatuses:["LOCSTATUS_COMPLETED","LOCSTATUS_RECRUITMENT_COMPLETE"],DisplayValue:a.locationSortByStatusLabels.completedLabel},{InternalValue:"LOCSTATUS_OTHER",AvailableStatuses:["LOCSTATUS_OTHER","LOCSTATUS_TERMINATED"],DisplayValue:a.locationSortByStatusLabels.otherLabel}],o=e=>{i.current&&!i.current.contains(e.target)&&n(!1)};return(0,d.useEffect)(()=>(document.addEventListener("click",e=>o(e)),()=>{document.removeEventListener("click",e=>o(e))}),[]),(0,s.jsxs)("div",{className:"relative flex sm:w-auto w-full bg-white font-secondary",ref:i,children:[(0,s.jsxs)("button",{onClick:()=>{n(!l),(0,x.u)("ToggleDropdown",{category:"Dropdown",action:"Click",label:`Dropdown is open: ${!l}`})},type:"button",className:"relative font-secondary italic flex items-center justify-between border border-gray-default px-4 py-3 w-full sm:w-auto min-w-[240px]",children:[(0,s.jsxs)("span",{className:"flex items-center",children:[U(e.InternalValue)," ",e.DisplayValue]}),(0,s.jsx)("span",{className:"absolute right-0 top-0 mr-4 text-xl h-full flex items-center",children:(0,s.jsx)(f.FaSort,{className:"w-[19px] h-[19px]"})})]}),(0,s.jsx)("ul",{className:`${l?"block":"hidden"} w-full absolute bg-white italic text-base leading-5 shadow-container mt-2 z-10 border border-gray-default px-4 py-1`,style:{top:"100%"},children:r.map((e,a)=>(0,s.jsxs)("li",{onClick:()=>{t(e),n(!1),(0,x.u)("ToggleDropdown",{category:"Dropdown",action:"Click",label:"Dropdown is closed"})},className:"cursor-pointer italic flex items-center py-3 border-b last:border-b-0 border-divider",children:[U(e.InternalValue),e.DisplayValue]},a))})]})},Z=R()(()=>Promise.all([a.e(759),a.e(831),a.e(230)]).then(a.bind(a,2230)),{loadableGenerated:{webpack:()=>[2230]},ssr:!1,loading:()=>(0,s.jsx)("div",{className:"w-full rounded-lg bg-gray-100 animate-pulse",style:{height:600},"aria-hidden":!0})}),B=({study:e,labels:t})=>{let[a,i]=(0,d.useState)(null),[l,n]=(0,d.useState)(null),[r,o]=(0,d.useState)([]),{Latitude:c,Longitude:u,LocationName:m,MileRadius:h}=(0,p.useRouter)().query,[f,b]=(0,d.useState)({InternalValue:null,AvailableStatuses:[],DisplayValue:t.locationSortByStatusLabels.defaultValue}),x=["RECSTATUS_COMPLETED","RECSTATUS_STUDY_COMPLETED","RECSTATUS_RECRUITMENT_ON_HOLD","RECSTATUS_TERMINATED","RECSTATUS_OTHER","RECSTATUS_NOT_YET_REC"].includes(e.display_status_internal),y=["Recruiting","Unknown","Available"],g=["Withdrawn","Terminated"],w=()=>y.includes(e.overall_status)?e.locations:e.locations.filter(e=>!g.includes(e.StatusDisplay)),v=(0,d.useCallback)(e=>{i(e),n(e)},[]),T=(0,d.useMemo)(()=>({site:"Site Title",conditions:"Condition",StudyId:"Study ID",City:"City",StateDisplay:"State",PostalCode:"Zip",CountryDisplay:"Country"}),[]),D=(0,d.useMemo)(()=>({width:26,height:32}),[]),C=(0,d.useRef)(null),[_,S]=(0,d.useState)(!1);return(0,d.useEffect)(()=>{let e=C.current;if(!e||_)return;let t=new IntersectionObserver(e=>{e[0]?.isIntersecting&&(S(!0),t.disconnect())},{root:null,rootMargin:"280px 0px",threshold:0});return t.observe(e),()=>t.disconnect()},[_]),(0,d.useEffect)(()=>{let t=w().map(t=>({...t,StudyId:e.org_study_id,conditions:e.conditions&&e.conditions.length?e.conditions.map(e=>e.DisplayValue).filter((e,t,a)=>a.indexOf(e)===t).join(", "):"N/A"}));t=(0,P.JL)(t,c,u,m||"",h),f.InternalValue&&(t=t.filter(e=>f.AvailableStatuses.includes(e.StatusDisplayInternal)).map(e=>e)),o(t)},[f]),(0,d.useEffect)(()=>{let t=a;t||(t=w().map(t=>({...t,StudyId:e.org_study_id,conditions:e.conditions&&e.conditions.length?e.conditions.map(e=>e.DisplayValue).filter((e,t,a)=>a.indexOf(e)===t).join(", "):"N/A",distance:void 0}))),f.InternalValue&&t.length>0?n(t.filter(e=>f.AvailableStatuses.includes(e.StatusDisplayInternal))):n(t)},[f,a]),(0,s.jsxs)("div",{className:"max-w-container map-wrapper mx-auto pb-6 md:pb-0 px-2 md:px-4",children:[(0,s.jsx)("div",{ref:C,children:_?(0,s.jsx)(Z,{data:T,studyLocations:r,setActiveLoc:v,isDynamic:!0,initialZoom:c&&u?13:3,isMarkerInfoWinow:!0,infoWindowMaxWidth:350,isCluster:!0,icon:"/assets/icons/map-marker.svg",iconSize:D}):(0,s.jsx)("div",{className:"w-full rounded-lg bg-gray-100 animate-pulse",style:{height:600},"aria-hidden":!0})}),x?null:(0,s.jsxs)("div",{className:"flex flex-wrap items-center justify-end mt-6",children:[(0,s.jsxs)("div",{className:"pr-4 font-bold italic text-base leading-5 font-secondary",children:[t.locationSortByStatusLabels.label," "]}),(0,s.jsx)(F,{activeOption:f,setActiveOption:b,labels:t})]}),l&&l.length>0?(0,s.jsx)($,{locations:l,internalStatus:e.display_status_internal,hide
2Status:!y.includes(e.overall_status)}):(0,s.jsx)("p",{className:"text-center mt-6 font-bold text-gray",children:"No locations available"})]})},J=["\n\n","\n"],z=e=>(e&&J.forEach(t=>{e.indexOf(t)>-1&&(e=e.replace(RegExp(t,"g"),"</li><li>"))}),e),V=({study:e,labels:t})=>{let a,i=(0,d.useRef)(null),[l,n]=(0,d.useState)({summary:!1,description:!1,locations:!1,publications:!1}),r="bg-white p-5 md:py-6 md:px-8 relative",o="hidden md:block h-16 w-16 text-details_icon opacity-30 float-right -mt-2 -mr-4",c="text-primary-claret font-secondary font-light mb-1 text-base leading-[22px]";return(0,s.jsxs)(s.Fragment,{children:[(0,s.jsxs)("div",{className:"relative",children:[(0,s.jsx)("div",{className:"hidden md:block bg-gray-default absolute h-20 w-full"}),(0,s.jsx)("div",{className:"max-w-container mx-auto md:px-4 xl:px-0 -mt-[1px]",children:(0,s.jsxs)("div",{className:"grid grid-cols-2 md:grid-cols-3 gap-px bg-divider pb-[1px] md:drop-shadow-custom",children:[(0,s.jsxs)("div",{className:`${r} md:col-span-3 col-span-2`,children:[(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.officialTitleLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.official_title||"-"})]}),(0,s.jsxs)("div",{className:r,children:[(0,s.jsx)(f.FaStethoscope,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.medicalConditionLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.conditions?(a=[],e.conditions.filter(e=>!a.includes(e.DisplayValue)&&(a.push(e.DisplayValue),!0))).map(e=>e.LookupValue).join(", "):"-"})]}),(0,s.jsxs)("div",{className:r,children:[(0,s.jsx)(f.FaLayerGroup,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.phaseLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.display_phase||"-"})]}),(0,s.jsxs)("div",{className:r,children:[(0,s.jsx)(f.FaHeart,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.healthyVolunteersLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.healthy_volunteers||"-"})]}),(0,s.jsxs)("div",{className:r,children:[(0,s.jsx)(f.FaSyringe,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.studyDrugLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray whitespace-pre-line",children:e.interventions.filter((e,t,a)=>t===a.findIndex(t=>t.intervention_name===e.intervention_name)).filter(e=>"Drug"===e.intervention_type||"Biological"===e.intervention_type).map(e=>`${e.intervention_name}`).join(", \n")||"-"})]}),(0,s.jsxs)("div",{className:r,children:[(0,s.jsx)(f.FaTransgender,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.genderLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.display_gender||"-"})]}),(0,s.jsxs)("div",{className:r,children:[(0,s.jsx)(f.FaUsers,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:(()=>{switch(e.display_status_internal){case"RECSTATUS_RECRUITING":case"RECSTATUS_WILL_BE_RECRUITING":case"RECSTATUS_NOT_YET_REC":return t.studyDetailsLabels.estimatedEnrollmentLabel;default:return t.studyDetailsLabels.enrollmentLabel}})()}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.enrollment||"-"})]}),(0,s.jsxs)("div",{className:r,children:[(0,s.jsx)(f.FaBriefcaseMedical,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.typeLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.study_type||"-"})]}),(0,s.jsxs)("div",{className:r,children:[(0,s.jsx)(f.FaUserFriends,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.ageLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:((e,t)=>{switch(!0){case!e.includes("N/A")&&!t.includes("N/A"):return`${e} - ${t}`;case!e.includes("N/A"):return`${e} +`;case!t.includes("N/A"):return`N/A - ${t}`;default:return"N/A"}})(e.minimum_age_raw,e.maximum_age_raw)||"-"})]}),(0,s.jsxs)("div",{className:`${r} col-span-2 md:col-span-1`,children:[(0,s.jsx)(b.vxJ,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.dateLabel}),(0,s.jsxs)("div",{className:"font-light text-xl font-third leading-8 text-gray",children:[(0,s.jsxs)("div",{children:[(0,s.jsx)("b",{children:t.studyDetailsLabels.studyStartDateLabel})," ",e.start_date?`${new Date(e.start_date).toLocaleDateString("en-GB",{day:"2-digit",month:"short",year:"numeric"})}`:"-"]}
2),(0,s.jsxs)("div",{children:[(0,s.jsxs)("b",{children:["Anticipated"===e.primary_compl_date_type?`${t.studyDetailsLabels.estimatedLabel} `:"",t.studyDetailsLabels.primaryCompletionDateLabel]})," ",e.primary_compl_date?`${new Date(e.primary_compl_date).toLocaleDateString("en-GB",{day:"2-digit",month:"short",year:"numeric"})}`:"-"]}),(0,s.jsxs)("div",{children:[(0,s.jsxs)("b",{children:["Anticipated"===e.last_follow_up_date_type?`${t.studyDetailsLabels.estimatedLabel} `:"",t.studyDetailsLabels.studyCompletionDateLabel]})," ",e.last_follow_up_date?`${new Date(e.last_follow_up_date).toLocaleDateString("en-GB",{day:"2-digit",month:"short",year:"numeric"})}`:"-"]})]})]}),(0,s.jsxs)("div",{className:`${r} col-span-2 md:col-span-1 md:-mb-[1px]`,children:[(0,s.jsx)(b.o_h,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.studyDesignLabel}),(0,s.jsxs)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:[t.studyDetailsLabels.allocationLabel," ",e.allocation||"-"," ",(0,s.jsx)("br",{}),t.studyDetailsLabels.endpointClassificationLabel," ",e.endpoint||"-"," ",(0,s.jsx)("br",{}),t.studyDetailsLabels.interventionModelLabel," ",e.assignment||"-"," ",(0,s.jsx)("br",{}),t.studyDetailsLabels.maskingLabel," ",e.masking||"-"," ",(0,s.jsx)("br",{}),t.studyDetailsLabels.primayPurposeLabel," ",e.interventional_subtype||"-"," ",(0,s.jsx)("br",{})]})]}),(0,s.jsxs)("div",{className:`${r} col-span-2 md:col-span-1 md:-mb-[1px]`,children:[(0,s.jsx)(f.FaCheck,{className:o}),(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.verificationLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.verification_date?`${t.studyDetailsLabels.verifiedLabel} ${new Date(e.verification_date).toLocaleDateString("en-GB",{day:"2-digit",month:"short",year:"numeric"})}${e.sponsors.lead_sponsor?` ${t.studyDetailsLabels.byLabel} ${e.sponsors.lead_sponsor}`:""}`:"-"})]}),(0,s.jsxs)("div",{className:`${r} col-span-2 md:col-span-1 -mb-[1px]`,children:[(0,s.jsx)(f.FaUserTie,{className:o}),(0,s.jsxs)("div",{children:[(0,s.jsxs)("div",{children:[(0,s.jsx)("h3",{className:`${c}`,children:t.studyDetailsLabels.sponsorsLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.sponsors?.lead_sponsor||"-"})]}),(0,s.jsxs)("div",{children:[(0,s.jsx)("h3",{className:`${c} pt-2`,children:t.studyDetailsLabels.collaboratorsLabel}),(0,s.jsx)("p",{className:"font-light text-xl font-third leading-8 text-gray",children:e.sponsors?.collaborators.length>0?e.sponsors.collaborators.join(", "):"-"})]})]})]})]})})]}),(0,s.jsxs)("div",{children:[(0,s.jsx)("div",{className:"relative bg-[#F8F8F8] md:bg-transparent",children:(0,s.jsx)(h.Y,{children:(0,s.jsx)("div",{className:"md:py-16 md:border-b-[3px] border-[#9DB0AC] relative z-20",children:(0,s.jsxs)("div",{className:"flex flex-col md:flex-row justify-between items-start md:items-center py-6 px-1 md:px-10 bg-[#F8F8F8] print:flex-col",children:[(0,s.jsx)("span",{className:"text-primary-claret font-secondary font-light text-xl md:text-2xl leading-[22px] md:leading-[22px] pb-4 md:pb-0 print:text-2xl",children:t.studyDetailsLabels.inclusionExclusionHeadline}),(0,s.jsxs)("button",{onClick:()=>{i.current?.open(),(0,x.u)("Show criteria modal",{category:"Modal",action:"Click",label:"Show criteria modal"})},className:"border print:hidden border-gray-default text-gray py-3 px-6 font-secondary font-bold italic flex items-center text-base leading-[19px] criteria-btn",children:[(0,s.jsx)("span",{className:"mr-2.5 border-b-2 border-gray border-opacity-0 transition-all duration-300",children:t.studyDetailsLabels.readCriteriaButton}),(0,s.jsx)(b.xyO,{className:"h-5 w-5 text-gray-default inline-block ml-2"})]}),(0,s.jsxs)("div",{className:"w-full flex-col mt-4 font-light font-secondary text-gray hidden print:block",children:[e.inclusion&&(0,s.jsxs)("div",{children:[(0,s.jsx)("h5",{className:"text-2xl font-bold leading-7 mb-4 font-secondary",children:"Inclusion Criteria"}),(0,s.jsx)("ul",{className:"text-sm leading-6 font-third whitespace-pre-wrap",dangerouslySetInnerHTML:{__html:`<li>${z(e.inclusion)}</li>`}})]}),e.exclusion&&(0,s.jsxs)("div",{className:"mt-8 md:mt-12",children:[(0,s.jsx)("h5",{className:"text-2xl font-bold leading-7 mb-4 font-secondary",children:"Exclusion Criteria"}),(0,s.jsx)("ul",{className:"text-sm leading-6 font-third whitespace-pre-wrap",dangerouslySetInnerHTML:{__html:`<li>${z(e.exclusion)}</li>`}})]})]})]})})})}),(0,s.jsx)("div",{className:"relative border-b md:border-b-0 border-[#D8DADA]",children:(0,s.jsx)(h.Y,{children:(0,s.jsxs)("div",{className:"md:py-16 md:border-b-[3px] border-[#9DB0AC] relative z-20",children:[(0,s.jsxs)("button",{className:"w-full flex justify-between py-7.5 pl-2 md:pl-6 pr-3.5 md:pr-7 focus:outline-none focus-visible:underline",onClick:()=>{n({...l,summary:!l.summary}),(0,x.u)("Set blocks summary",{category:"Blocks",action:"Click",label:`Blocks summary: ${!l.summary}`})},children:[(0,s.jsx)("span",{className:"text-primary-claret font-secondary font-light text-2xl leading-8",children:t.studyDetailsLabels.protocolSummaryHeadline}),(0,s.jsx)("span",{className:"outline-none",children:(0,s.jsx)(b.tEr,{className:`h-6 w-6 text-gray-default ${l.summary?"rotate-180":""}`})})]}),(0,s.jsx)("p",{className:`pl-2 md:pl-6 pb-4 text-xl leading-8 font-third font-light md:pb-0 pr-2 md:pr-7.5 ${l.summary?"":"hidden"} print:block `,children:e.brief_summary})]})})}),e.detailed_description?(0,s.jsx)("div",{className:"relative border-b md:border-b-0 border-[#D8DADA]",children:(0,s.jsx)(h.Y,{children:(0,s.jsxs)("div",{className:"md:py-16 md:border-b-[3px] border-[#9DB0AC] relative z-20",children:[(0,s.jsxs)("button",{className:"w-full flex justify-between py-7.5 pl-2 md:pl-6 pr-3.5 md:pr-7 focus:outline-none focus-visible:underline",onClick:()=>{n({...l,description:!l.description}
2),(0,x.u)("Set blocks description",{category:"Blocks",action:"Click",label:`Blocks description: ${!l.description}`})},children:[(0,s.jsx)("span",{className:"text-primary-claret font-secondary font-light text-2xl leading-8",children:t.studyDetailsLabels.detailedDescriptionHeadline}),(0,s.jsx)("span",{children:(0,s.jsx)(b.tEr,{className:`h-6 w-6 text-gray-default ${l.description?"rotate-180":""}`})})]}),(0,s.jsx)("p",{className:`pl-2 md:pl-6 pb-4 text-xl leading-8 font-third font-light md:pb-0 pr-2 md:pr-7.5 whitespace-pre-line ${l.description?"":"hidden"} print:block`,children:e.detailed_description})]})})}):null,(0,s.jsx)("div",{className:"relative border-b md:border-b-0 border-[#D8DADA]",children:(0,s.jsx)(h.Y,{children:(0,s.jsxs)("div",{className:"md:py-16 md:border-b-[3px] border-[#9DB0AC] relative z-20",children:[(0,s.jsxs)("button",{className:"w-full flex justify-between py-7.5 pl-2 md:pl-6 pr-3.5 md:pr-7 focus:outline-none focus-visible:underline",onClick:()=>{n({...l,locations:!l.locations}),(0,x.u)("Set blocks locations",{category:"Blocks",action:"Click",label:`Blocks locations: ${!l.locations}`})},children:[(0,s.jsx)("span",{className:"text-primary-claret font-secondary font-light text-2xl leading-8",children:t.studyDetailsLabels.studyLocationsHeadline}),(0,s.jsx)("span",{children:(0,s.jsx)(b.tEr,{className:`h-6 w-6 text-gray-default ${l.locations?"rotate-180":""}`})})]}),(0,s.jsx)("div",{className:`locations-wrapper ${l.locations?"visible h-auto":"invisible h-0 overflow-hidden"} print:block`,children:(0,s.jsx)(B,{study:e,labels:t})})]})})}),(0,s.jsx)("div",{className:"relative",children:(0,s.jsx)(h.Y,{children:(0,s.jsxs)("div",{className:"md:py-16",children:[(0,s.jsxs)("button",{className:"w-full flex justify-between py-7.5 pl-2 md:pl-6 pr-3.5 md:pr-7 focus:outline-none focus-visible:underline",onClick:()=>n({...l,publications:!l.publications}),children:[(0,s.jsx)("span",{className:"text-primary-claret font-secondary font-light text-2xl leading-8",children:t.studyDetailsLabels.clinicalPublicationsHeadline}),(0,s.jsx)("span",{children:(0,s.jsx)(b.tEr,{className:`h-6 w-6 text-gray-default ${l.publications?"rotate-180":""}`})})]}),(0,s.jsx)("div",{className:`pl-2 md:pl-6 pb-8 ${l.publications?"":"hidden"} print:block `})]})})})]}),(0,s.jsx)(I.a,{ref:i,containerClassName:"view-documents-modal flex items-start justify-start mt-10 font-primary",overlayClassName:"px-4 criteria bg-background-popup-overlay",size:"large",children:(0,s.jsxs)("div",{className:"w-full flex flex-col mt-4 font-light font-secondary text-gray",children:[(0,s.jsx)("h4",{className:"text-3.5xl md:text-[42px] leading-[56px] mb-6 italic ",children:"Inclusion and Exclusion Criteria:"}),e.inclusion&&(0,s.jsxs)("div",{children:[(0,s.jsx)("h5",{className:"text-2xl font-bold leading-7 mb-4 font-secondary",children:"Inclusion Criteria"}),(0,s.jsx)("ul",{className:"text-sm leading-6 font-third whitespace-pre-wrap",dangerouslySetInnerHTML:{__html:`<li>${z(e.inclusion)}</li>`}})]}),e.exclusion&&(0,s.jsxs)("div",{className:"mt-8 md:mt-12",children:[(0,s.jsx)("h5",{className:"text-2xl font-bold leading-7 mb-4 font-secondary",children:"Exclusion Criteria"}),(0,s.jsx)("ul",{className:"text-sm leading-6 font-third whitespace-pre-wrap",dangerouslySetInnerHTML:{__html:`<li>${z(e.exclusion)}</li>`}})]})]})})]})},W=({study:e,labels:t})=>{let a=e.overall_contact.first_name||e.overall_contact.last_name||e.overall_contact.phone||e.overall_contact.email,i=e.overall_contact_backup.first_name||e.overall_contact_backup.last_name||e.overall_contact_backup.phone||e.overall_contact_backup.email,l=e.overall_official.first_name||e.overall_official.last_name||e.overall_official.affiliation;return(0,s.jsx)(h.Y,{children:(0,s.jsxs)("div",{className:"flex flex-wrap py-12",children:[(a||i||l)&&(0,s.jsxs)("div",{className:"md:w-1/2 md:pb-0 pb-6 md:pr-4",children:[(0,s.jsx)("h3",{className:"font-secondary mb-4 font-light text-[23px] leading-[29px] text-primary-claret",children:t.contactLabels.contactTabLabel}),a&&(0,s.jsxs)("div",{className:"flex flex-col text-gray-default font-third",children:[(0,s.jsx)("h4",{className:"text-xl leading-8 mb-2 font-bold",children:t.contactLabels.contactLabel}),(0,s.jsxs)("div",{className:"flex items-center mb-2",children:[(0,s.jsx)(b.Rlz,{className:"inline-block text-[32px] min-w-[24px] mr-2 text-divider "}),(0,s.jsx)("span",{className:" text-xl leading-8 font-light",children:e.overall_contact.first_name||e.overall_contact.last_name?`${e.overall_contact.first_name} ${e.overall_contact.last_name}`:"-"})]}),(0,s.jsxs)("div",{className:"flex items-center mb-2",children:[(0,s.jsx)(b.NnP,{className:"inline-block w-6 h-6 mr-4 text-divider"}),(0,s.jsx)("span",{className:" text-xl leading-8 font-light",children:e.overall_contact?.phone?(0,s.jsx)("a",{href:`tel:${e.overall_contact.phone}`,children:e.overall_contact.phone}):"-"})]}),(0,s.jsxs)("div",{className:"flex items-center",children:[(0,s.jsx)(f.FaEnvelope,{className:"inline-block w-6 h-6 mr-4 text-divider"}),(0,s.jsx)("span",{className:" text-xl leading-8 font-light",children:e.overall_contact?.email?(0,s.jsx)("a",{href:`mailto:${e.overall_contact.email}`,children:e.overall_contact.email}):"-"})]})]}),i&&(0,s.jsxs)("div",{className:"flex flex-col text-gray-default font-third mt-4",children:[(0,s.jsx)("h4",{className:"text-xl leading-8 mb-2 font-bold",children:t.contactLabels.contactBackupLabel}),(0,s.jsxs)("div",{className:"flex items-center mb-2",children:[(0,s.jsx)(b.Rlz,{className:"inline-block text-3xl leading-8 min-w-[24px] mr-4 text-divider "}),(0,s.jsx)("span",{className:" text-xl leading-8 font-light",children:e.overall_contact_backup.first_name||e.overall_contact_backup.last_name?`${e.overall_contact_backup.first_name} ${e.overall_contact_backup.last_name}`:"-"})]}),(0,s.jsxs)("div",{className:"flex items-center mb-2",children:[(0,s.jsx)(b.NnP,{className:"inline-block w-6 h-6 mr-4 text-divider"}),(0,s.jsx)("span",{className:" text-xl leading-8 font-light",children:e.overall_contact_backup?.phone?(0,s.jsx)("a",{href:`tel:${e.overall_contact_backup.phone}`,children:e.overall_contact_backup.phone}):"-"})]}),(0,s.jsxs)("div",{className:"flex items-center",children:[(0,s.jsx)(f.FaEnvelope,{className:"inline-block w-6 h-6 mr-4 text-divider"}),(0,s.jsx)("span",{className:" text-xl leading-8 font-light",children:e.overall_contact_backup?.email?(0,s.jsx)("a",{href:`mailto:${e.overall_contact_backup.email}`,children:e.overall_contact_backup.email}):"-"})]})]})]}),l&&(0,s.jsxs)("div",{className:"md:w-1/2 md:pl-4",children:[(0,s.jsx)("h3",{className:"font-secondary mb-4 font-light text-[23px] leading-[29px] text-primary-claret",children:t.contactLabels.investigatorsLabel}),(0,s.jsxs)("div",{className:"flex flex-col text-gray-default font-third",children:[(0,s.jsx)("h4",{className:"text-xl leading-8 mb-2 font-bold",children:t.contactLabels.principalInvestigatorLabel}),(0,s.jsxs)("div",{className:"flex items-center mb-2",children:[(0,s.jsx)(f.FaUserNurse,{className:"inline-block text-2xl mr-4 text-divider "}),(0,s.jsx)("span",{className:" text-xl leading-8 font-light",children:e.overall_official.first_name||e.overall_official.last_name?`${e.overall_official.first_name} ${e.overall_official.middle_name} ${e.overall_official.last_name}`:"-"})]}),(0,s.jsxs)("div",{className:"flex items-center mb-2",children:[(0,s.jsx)(f.FaUniversity,{className:"inline-block text-2xl mr-4 text-divider "}),(0,s.jsx)("span",{className:" text-xl leading-8 font-light",children:e.overall_official.affiliation||"-"})]})]})]})]})})},G=({study:e,labels:t})=>(0,s.jsx)(h.Y,{className:"py-12",children:(0,s.jsxs)("table",{className:"table-auto",children:[(0,s.jsx)("thead",{children:(0,s.jsxs)("tr",{children:[(0,s.jsxs)("th",{className:"md:w-1/2",children:[" ",t.armsLabels.armsLabel]}),(0,s.jsx)("th",{className:"text-center",children:t.armsLabels.assignedInterventionsLabel})]})}),(0,s.jsx)("tbody",{children:e.arm_groups.map(t=>{let a=e.interventions.filter(e=>e.arm_group_label===t.arm_group_label),i=a.filter(e=>e.intervention_description);return(0,s.jsxs)("tr",{children:[(0,s.jsxs)("td",{children:[t.arm_type?`${t.arm_type}: `:"",t.arm_group_label,(0,s.jsx)("br",{}),t.arm_group_description]}),(0,s.jsx)("td",{className:"whitespace-pre-line",children:a.length>0&&i.length>0?i.map((e,t)=>(0,s.jsxs)("div",{className:"mb-2 last:mb-0",children:[e.intervention_type?`${e.intervention_type}: `:"",e.intervention_name," ",(0,s.jsx)("br",{}),e.intervention_description,e.intervention_other_name&&e.intervention_other_name.map((e,t)=>e?(0,s.jsxs)("p",{children:["Other Name: ",e]},`other-name-${t}-${e}`):"")]},e.intervention_name||`intervention-${t}`)):"-"})]},t.arm_group_label||`arm-${t.arm_type}`)})})]})});var Y=a(1327);let K=({study:e,labels:t})=>{let[a,i]=(0,d.useState)(0),l="py-3 px-4 mr-2 border border-white border-b-0 font-secondary italic focus:outline-none focus-visible:outline-primary-claret focus-visible:outline-offset-[-5px] whitespace-nowrap",n=e=>{let t=Object.values(e).filter(e=>null!==e);return!!t.length&&!!t.filter(e=>!!e&&!!Object.values(e).filter(e=>null!==e).length).length},r=()=>!!e&&(!!e.overall_contact.email||!!e.overall_contact.phone||!!e.overall_contact.first_name||!!e.overall_contact.last_name||!!e.overall_contact_backup.email||!!e.overall_contact_backup.first_name||!!e.overall_contact_backup.last_name||!!e.overall_contact.phone||!!e.overall_official.first_name||!!e.overall_official.last_name||!!e.overall_official.affiliation)||!1,[o,c]=(0,d.useState)("");return(0,d.useEffect)(()=>{(0,Y.$H)(e.org_study_id).then(e=>{"Value"===e.tag?c(e.value):console.log("Error!")})},[]),(0,s.jsxs)("div",{children:[(0,s.jsxs)(h.Y,{backgroundColor:"#3C4242",children:[(0,s.jsxs)("div",{className:"flex justify-start items-center text-white py-6.5",children:[(()=>{switch(e.display_status_internal){case"RECSTATUS_RECRUITING":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-4 text-study_status-recruiting"});case"RECSTATUS_WILL_BE_RECRUITING":case"RECSTATUS_NOT_YET_REC":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-4 text-study_status-not_yet_recruiting"});case"RECSTATUS_RECRUITMENT_COMPLETE":case"RECSTATUS_COMPLETED":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-4 text-study_status-recruiting_complete"});case"RECSTATUS_STUDY_COMPLETE":case"RECSTATUS_STUDY_COMPLETED":return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-4 text-study_status-completed"});default:return(0,s.jsx)(f.FaCircle,{className:"h-4 w-4 mr-4 text-study_status-other"})}})(),(0,s.jsx)("span",{className:"font-secondary italic text-base leading-5",children:e.display_status})]}),(0,s.jsxs)("div",{className:"text-sm flex overflow-auto -webkit-overflow-scrolling-touch",style:{touchAction:"pan-x"},children:[(e.result&&n(e.result)||e.links&&e.links.length>0||e.attachments&&e.attachments.length>0||r()||e.arm_groups&&e.arm_groups.length>0)&&(0,s.jsx)("button",{onClick:()=>{i(0),(0,x.u)("Set Active Tab",{category:"Tab",action:"Click",label:"Active tab: 0"})},className:`${l} ${0===a?"text-gray bg-white":"text-white"}`,children:t.studyDetailsLabels.overviewTabButton}),e.arm_groups&&e.arm_groups.length>0&&(0,s.jsx)("button",{onClick:()=>{i(1),(0,x.u)("Set Active Tab",{category:"Tab",action:"Click",label:"Active tab: 1"})},className:`${l} ${1===a?"text-gray bg-white":"text-white"}`,children:t.armsLabels.armsTabLabel}),e.result&&n(e.result)&&(0,s.jsx)("button",{onClick:()=>{i(2),(0,x.u)("Set Active Tab",{category:"Tab",action:"Click",label:"Active tab: 2"})},className:`${l} ${2===a?"text-gray bg-white":"text-white"}`,children:t.studyDetailsLabels.resultsTabButton}),(e.links&&e.links.length>0||e.attachments&&e.attachments.length>0)&&(0,s.jsx)("button",{onClick:()=>{i(3),(0,x.u)("Set Active Tab",{category:"Tab",action:"Click",label:"Active tab: 3"})},className:`${l} ${3===a?"text-gray bg-white":"text-white"}`,children:t.studyDetailsLabels.documentsTabButton}),r()&&(0,s.jsx)("button",{onClick:()=>{i(4),(0,x.u)("Set Active Tab",{category:"Tab",action:"Click",label:"Active tab: 4"})},className:`${l} ${4===a?"text-gray bg-white":"text-white"}`,children:t.contactLabels.contactTabLabel})]})]}),(0,s.jsx)("div",{className:`${0===a?"":"invisible overflow-hidden h-0 w-0"}`,children:(0,s.jsx)(V,{study:e,labels:t})}),(0,s.jsx)("div",{className:`${1===a?"":"invisible overflow-hidden h-0 w-0"}`,children:(0,s.jsx)(G,{study:e,labels:t})}),(0,s.jsx)("div",{className:`results max-w-container mx-auto md:px-4 xl:px-0 -mt-[1px] ${2===a?"":"invisible overflow-hidden h-0 w-0"}`,children:(0,s.jsx)("div",{className:"text-sm leading-6 font-third whitespace-normal",dangerouslySetInnerHTML:{__html:o}})}),(e.links&&e.links.length>0||e.attachments&&e.attachments.length>0)&&(0,s.jsx)("div",{className:`${3===a?"":"invisible overflow-hidden h-0 w-0"}`,children:(0,s.jsx)(E,{attachments:(e.attachments||[]).filter(e=>null!==e.description&&void 0!==e.description),links:(e.links||[]).filter(t=>null!==t.description&&void 0!==t.description&&!(e.attachments||[]).some(e=>e.url===t.url||e.Url===t.url)),studyNctId:e.nct_number})}),(0,s.jsx)("div",{className:`${4===a?"":"invisible overflow-hidden h-0 w-0"}`,children:(0,s.jsx)(W,{study:e,labels:t})})]})};var q=a(6191),X=a(2115);let Q=(0,q.J1)` 3 query GET_DETAILS_PAGE( 4 $where: AstrazenecaWebsitesWhereInput! 5 $take: Int 6 $astrazenecaPageTrialDetailsWhere2: AstrazenecaPageTrialDetailsWhereInput! 7 $armsLabelsWhere2: AstrazenecaArmsLabelsWhereInput! 8 $contactLabelsWhere2: AstrazenecaDetailsContactLabelsWhereInput! 9 $detailsLabelsWhere2: AstrazenecaDetailsLabelsWhereInput! 10 $locationSortByStatusDropdownWhere2: AstrazenecaLocationSortByStatusDropdownWhereInput! 11 $publicationsLinkWhere2: AstrazenecaNavigationLinkWhereInput! 12 $resultsTabWhere2: AstrazenecaTabTrialResultsWhereInput! 13 ) { 14 gqlAstrazenecaWebsites(where: $where) { 15 astrazenecaPageTrialDetails( 16 take: $take 17 where: $astrazenecaPageTrialDetailsWhere2 18 ) { 19 armsLabels(where: $armsLabelsWhere2) { 20 armsLabel 21 armsTabLabel 22 assignedInterventionsLabel 23 } 24 contactLabels(where: $contactLabelsWhere2) { 25 contactBackupLabel 26 contactLabel 27 contactTabLabel 28 investigatorsLabel 29 principalInvestigatorLabel 30 } 31 detailsLabels(where: $detailsLabelsWhere2) { 32 ageLabel 33 allocationLabel 34 byLabel
35 clinicalPublicationsHeadline 36 collaboratorsLabel 37 dateLabel 38 detailedDescriptionHeadline 39 documentsHeadline 40 documentsTabButton 41 downloadButton 42 emailLeadText 43 emailNote 44 endpointClassificationLabel 45 enrollmentLabel 46 estimatedEnrollmentLabel 47 estimatedLabel 48 genderLabel 49 healthyVolunteersLabel 50 inclusionExclusionHeadline 51 interventionModelLabel 52 maskingLabel 53 medicalConditionLabel 54 officialTitleLabel 55 overviewTabButton 56 phaseLabel 57 primaryCompletionDateLabel 58 primayPurposeLabel 59 printLabel 60 protocolSummaryHeadline 61 resultsTabButton 62 readCriteriaButton 63 returnToLabel 64 shareLabel 65 sponsorsLabel 66 studyCompletionDateLabel 67 studyDesignLabel 68 studyDrugLabel 69 studyLocationsHeadline 70 studyStartDateLabel 71 typeLabel 72 verificationLabel 73 verifiedLabel 74 } 75 heroIdentifierCtGovLabel 76 heroIdentifierCtisLabel 77 heroIdentifierEudraCtLabel 78 heroIdentifierStudyLabel 79 locationSortByStatusDropdown( 80 where: $locationSortByStatusDropdownWhere2 81 ) { 82 completedLabel 83 defaultValue 84 label 85 notYetRecruitingLabel 86 otherLabel 87 recruitingCompleteLabel 88 recruitingLabel 89 withdrawnLabel 90 } 91 publications 92 publicationsLink(where: $publicationsLinkWhere2) { 93 linkText 94 linkUrl 95 } 96 publishStatus 97 resultsTab(where: $resultsTabWhere2) { 98 additionalDescriptionTableHeader 99 allCauseMortalityHeadline 100 baselineCharacteristicsHeadline 101 baselineMeasuresHeadline 102 certainAgreementsHeadline 103 contactHeadline 104 emailTableHeader 105 frequencyThresholdHeadline 106 limitationsHeadline 107 limitationsTableHeader 108 measureDescriptionTableHeader 109 measureName 110 measureTypeTableHeader 111 measuredValuesHeadline 112 nameTableHeader 113 organizationTableHeader 114 otherAdverseEventsHeadline 115 outcomeMeasuresHeadline 116 overallStudyHeadline 117 overallStudyTableRow1 118 overallStudyTableRow2 119 overallStudyTableRow3 120 participantFlowHeadline 121 phoneTableHeader 122 populationDescriptionHeadline 123 populationDescriptionTableHeader 124 preAssignmentDetailsHeadline 125 preAssignmentDetailsTableHeader 126 recruitmentDetailsHeadline 127 recruitmentDetailsTableHeader 128 reportingGroupsTableHeader 129 reportingGroupsHeadline 130 safetyIssueTableHeader 131 thresholdTableHeader 132 timeFrameTableHeader 133 seriousAdverseEventsHeadline 134 } 135 } 136 } 137 } 138`,ee=e=>{if(!e)return;let t=null;return e&&e.gqlAstrazenecaWebsites&&(t=e.gqlAstrazenecaWebsites[0].astrazenecaPageTrialDetails[0]),{heroLabels:{studyIdentifier:t.heroIdentifierStudyLabel,ctGovIdentifier:t.heroIdentifierCtGovLabel,eudraCtIdentifier:t.heroIdentifierEudraCtLabel,ctisCtIdentifier:t.heroIdentifierCtisLabel},studyDetailsLabels:(0,X.oA)(t.detailsLabels[0]),resultsLabels:(0,X.zF)(t.resultsTab[0]),publicationsLink:(0,X.Cz)(t.publicationsLink[0]),contactLabels:(0,X.FX)(t.contactLabels[0]),armsLabels:(0,X.KW)(t.armsLabels[0]),locationSortByStatusLabels:(0,X.kH)(t.locationSortByStatusDropdown[0]),publications:t.publications}},et={16008:{newDescription:"Join our study to evaluate how warfarin and lanabecestat interact, measure blood clot prevention, track side effects. 5-week trial, AstraZeneca.",newTitle:"Lanabecestat and Warfarin Interaction Study: Clinical Trial"},D601HC00008:{newDescription:"Join AstraZeneca's phase I trial assesses adavosertib's safety, tolerability, PK, and anti-tumour activity in Japanese patients with advanced solid tumours.",newTitle:"Adavosertib Study in Japanese Patients with Advanced Solid Tumours"},D3460C00002:{newDescription:"Evaluate anifrolumab's efficacy and safety against placebo in systemic sclerosis patients; join our trial to aid research on this debilitating disease.",newTitle:"Daisy Trial: Anifrolumab's Effectiveness in Systemic Sclerosis"},"BY9010%2FM1-142":{newDescription:"Comparison of ciclesonide vs. fluticasone propionate in mild to moderate asthma. Learn more and join our clinical trial. ",newTitle:"Ciclesonide vs Fluticasone: Asthma Trial (12-75y) - AZ Clinical Study"},D910PC00001:{newDescription:"This trial aims to determine the efficacy and safety of Durvalumab in combination with other drugs for perioperative treatment in patients with bladder cancer.",newTitle:"Durvalumab Combination Treatment for Bladder Cancer Patients"},D4020C00033:{newDescription:"Pediatric trial assesses TOPROL-XL's effectiveness and safety in treating hypertension, seeking participants to help advance medical knowledge.",newTitle:"Dosage, Safety & Tolerance of TOPROL-XL\xae for Hypertensive Pediatric Subjects"},D081FC00001:{newDescription:"Join our trial investigating the effectiveness of maintenance Olaparib in gBRCA mutated metastatic pancreatic cancer post-platinum chemotherapy.",newTitle:"G-BRCA Pancreatic Cancer: Olaparib for Non-Progressing Cases"},D7460C00001:{newDescription:"Join our phase I trial for a new treatment: a double-blind study in healthy vasectomized subjects, assessing the safety of a single ascending dose.",newTitle:"AZD4041 Safety & Pharmacokinetics Study in Healthy Volunteers"},D967JC00001:{newDescription:"Join a clinical trial investigating T-DXd's efficacy and safety, with other anti-cancer agents, in HER2-positive Metastatic Breast Cancer.",newTitle:"T-DXd Combinations for HER2+ Breast Cancer | Phase 1b/2 Study"},D2451C00002:{newDescription:"A pediatric hypertension trial with candesartan cilexet
138il, offering a range of doses and a long-term treatment period. Help contribute to medical research.",newTitle:"Atacand Dose Study for Hypertensive Children (1-6 yrs)"},D5980R00076:{newDescription:"Join the CHOROS ORION study: Assessing patient outcomes with BGF treatment in Italy. Contribute to closing the knowledge gap and make an impact on your health.",newTitle:"Real-life Trixeo Treatment Outcomes: Clinical Trials"},D7830C00001:{newDescription:"Join AstraZeneca's trial: We are studying AZD2693's safety, PK, and effects in healthy subjects, including Chinese and Japanese individuals.",newTitle:"Safety, Tolerability & Activity Study of AZD2693"},D9483C00001:{newDescription:"Join our trial to study the effects of Sodium Zirconium Cyclosilicate on potassium and sodium excretion in healthy Chinese subjects following a specialized diet.",newTitle:"Safer Sodium Zirconium: Chinese Study - Clinical Trials"},D3461R00058:{newDescription:"Assess anifrolumab usage in real-world SLE treatment through the ERYTHRO study; Join AstraZeneca's clinical trial to contribute to advancing patient care.",newTitle:"Describing the Experience of SLE Patients: A Retrospective Chart Review Study"},D533AC00001:{newDescription:"Join our trial testing ceralasertib alone and with durvalumab in participants with unresectable or advanced melanoma and PD-(L)1 resistance.",newTitle:"Ceralasertib Treatment for PD-1 Resistant Melanoma: Trial"},"BY9010%2FM1-413":{newDescription:"Join our trial to investigate safety and effectiveness of ciclesonide nasal spray vs. placebo for seasonal allergic rhinitis caused by pollen. ",newTitle:"Ciclesonide Nasal Spray for Seasonal Allergic Rhinitis: Study"},"ACE-LY-004":{newDescription:"Join AstraZeneca's trial to investigate ACP-196's safety and efficacy in relapsed or refractory Mantle Cell Lymphoma, and contribute to improving patient care.",newTitle:"ACR-196 Study: A Promising Treatment for Mantle Cell Lymphoma"},D6800C00002:{newDescription:"Assessing AZD2373's safety and PK in healthy African participants: Join AstraZeneca's Phase 1 study to contribute to important research for a healthier future.",newTitle:"AZD2373 Study: Safety, Tolerability, PK & PD in Healthy Sub-Saharan Ancestry"},D8664C00008:{newDescription:"Join our study evaluating the effectiveness and safety of Zoladex in pre-menopausal women with advanced breast cancer. Help us find better treatment options!",newTitle:"Zoladex 10.8 mg: Administration in Pre-Menopausal women with ABC"},D5165C00001:{newDescription:"Join our trial on AZD9291 + MEDI4736 vs. AZD9291 alone in advanced EGFR T790M+ NSCLC. Evaluate efficacy and safety to contribute to medical advancements.",newTitle:"Comparison of AZD9291 + MEDI4736 vs AZD9291 Alone in NSCLC"},D4300C00016:{newDescription:"Join AstraZeneca's trial: Assessing bioavailability of 4 fostamatinib tablets in healthy males. Contribute to groundbreaking research, improving healthcare outcomes.",newTitle:"Bioavailability Study of Fostamatinib Tablets on Quintiles Volunteers"},D1690C00060:{newDescription:"Join our clinical trial! Compare dapagliflozin monotherapy with acarbose in inadequately controlled T2DM patients. Evaluate efficacy and safety.",newTitle:" Clinical Trial for T2DM Patients in China: Drug-Naive Phase IV Study"},D539EC00001:{newDescription:"Join our AstraZeneca trial! Investigating Anastrozole ODF's equivalence with Arimidex tablet after single oral administration. Be a part of groundbreaking research!",newTitle:"Arimidex Tablet vs Anastrozole ODF in Japanese Male Volunteers"},D5980C00034:{newDescription:"Reduced readmissions post-severe COPD flare-up: Join Breztri trial to assess its benefits vs. non-triple inhaled therapy. Help shape the future with AstraZeneca!",newTitle:"Ikanos COPD Study: Breztri vs. Non-Triple Therapy After US Hospitalization"},D933QC00001:{newDescription:"Join our clinical trial for LS-SCLC patients who completed concurrent chemoradiation therapy - Phase III study comparing Durvalumab and Durvalumab + Tremelimumab.",newTitle:"Tremelimumab & Durvalumab Study: Limited Stage Small-Cell Lung Cancer"},D6580C00004:{newDescription:"Join our AZD4831 safety study for healthy men. Find optimal dosage, minimize side effects, and support future drug studies. Stay at our center, 48-hour post-dose.",newTitle:"Phase I Safety and Pharmacokinetics of AZD4831: Clinical Trial"},D9721C00002:{newDescription:"Join our trial to study AZD5305 and darolutamide alone or in combination before prostate surgery in men with prostate cancer. Help uncover new treatment options.",newTitle:"Investigating AZD5305 Effects in Newly Diagnosed Prostate Cancer"},D4020C00001:{newDescription:"Join our AstraZeneca clinical trial on TOPROL-XL safety and effectiveness in hypertensive children and adolescents. 52-week study with pharmacokinetic analysis.",newTitle:"Pediatric Hypertension Study: Safety & Pharmacokinetics of TOPROL-XL\xae"},D6400C00004:{newDescription:"Join AstraZeneca trial! Assessing AZD9977's effects in healthy males. Quick, single-dose study to understand pharmacodynamics. Be a part of Phase I research!",newTitle:"Assessing Pharmacodynamic Effects of AZD9977 in Healthy Males"},D8850R00001:{newDescription:"Join AstraZeneca's COVID-19 trial in UPMC Health System to assess EVUSHELD's effectiveness against SARS-CoV-2 in real-world settings and help combat COVID-19.",newTitle:"UPMC eVusheld: Real-World Effectiveness for Clinical Trials"},D8210C00003:{newDescription:"Join our Asthma Study: Evaluate Efficacy, Safety & PK of AZD4604 in Adults with Uncontrolled Asthma. 12-week Treatment using Dry-Powder Inhaler. Join Now!",newTitle:"Phase 2a Study: Efficacy & Safety of AZD4604 in Moderate-Severe Asthma Patients"},D1220C00005:{newDescription:"Join our clinical trial! Find out how ZOMIG\xae Rapimelt affects 5-HT1B receptor occupancy in healthy males. Help us advance medical research with AstraZeneca.",newTitle:"ZOMIG Rapimelt: Central 5-HT1B Receptor Occupancy in Healthy Males"},D7000C00007:{newDescription:"Join our AZD3152 trial to prevent COVID-19! Learn about safety, tolerability, PK/PD profiles, and ADA generation. Help us fight the virus with AstraZeneca.",newTitle:"AZD3152 Injection & Infusion Study in Healthy Japanese Adults: Trials"},D5892C00015:{newDescription:"Join our clinical trial to explore how Symbicort and Spiriva combined treatment improves lung function, symptoms, and inflammation in severe COPD patients.",newTitle:"Combining Spiriva and
138Symbicort for Severe COPD: Efficacy & Safety Evaluation"},D1448C00003:{newDescription:"Join our AstraZeneca trial: Quetiapine fumarate (SEROQUEL XR) shows superior efficacy over placebo as mono-therapy for Major Depressive Disorders. Act now!",newTitle:"Seroquel SR: Treating Major Depressive Disorders "},D9673R00028:{newDescription:"Join our trial to observe outcomes of T-DXd in HER2+ or HER2-low breast cancer patients. We assess efficacy, safety, and include a digital healthcare app.",newTitle:"Prospective Interventional Study: Trastuzumab Deruxtecan in Breast Cancer"},D1691R00001:{newDescription:"Join our trial! Prospective study for adults with type 2 diabetes initiating Xigduo XR, regulated by MFDS. Help us improve patient care.",newTitle:"Xigduo XR: 's Clinical Trials & Post-Marketing Surveillance"},PT003005:{newDescription:"Join our trial: Compare Glycopyrrolate/Formoterol Fumarate MDI's efficacy to GP MDI and FF MDI in moderate to severe COPD. Help advance COPD treatment!",newTitle:"Comparing Glycopyrrolate/Formoterol Fumarate MDI to Spiriva\xae DPI in COPD"},"NIS-OJP-ARI-2007%2F1":{newDescription:"Join AstraZeneca's trial investigating bone fractures in post-menopausal breast cancer patients! Help shape the future of treatment with Arimidex 1mg.",newTitle:"Bone Fracture Retrospective Survey: Remidex 1mg in Trials"},"NIS-CRU-ONG-2010%2F1":{newDescription:"Join AstraZeneca's trial: Assessing glycemic control & physician satisfaction with DM2 OAD monotherapy. Contribute to research and make a difference!",newTitle:"Compensation Evaluation of DMT2 Patients on OAD Monotherapy"},D1444C00008:{newDescription:"Join AstraZeneca's trial evaluating the effectiveness of once-daily quetiapine fumarate XR as treatment for acute episodes in schizophrenic patients.",newTitle:"Safe & Effective Quetiapine Fumarate 400mg: Clinical Trial"},D8850R00006:{newDescription:"Join our study on pregnancy outcomes with EVUSHELD! Assessing real-world data from US, France, and Canada. Help advance research with AstraZeneca.",newTitle:"Evidence on EVUSHELD⢠Safety in Pregnancy: Multi-country Cohort Study"},D9230C00002:{newDescription:"Join us in measuring safety, tolerability & PK of AZD7503 in suspected NASH patients. Help advance liver disease research with AstraZeneca trials!",newTitle:"Investigating Safety & Pharmacokinetics of AZD7503 in NASH: Trial"},D589LC00003:{newDescription:"Compare tolerability of Symbicort\xae Turbuhaler\xae vs. terbutaline Turbuhaler\xae in adult asthma patients. Join AstraZeneca trials to make a difference!",newTitle:"Symbicort 160/4.5 Dosage: Safety & Efficacy in Japanese Patients "},D7830C00008:{newDescription:"Join AZ Clinical Trial: Administering AZD2693 Subcutaneously to Hepatic-Impaired Participants for Enhanced Treatment. Help Shape Future Medicine!",newTitle:"Effect of Hepatic Impairment on PK, Safety, & Tolerability of AZD2693"},D961FC00012:{newDescription:"Join AstraZeneca clinical trials - Compare bioavailability of Esomeprazole & Aspirin for multiple-dose administration. Discover ASA effectiveness!",newTitle:"Asa81 Study: Healthy Volunteers for 's Clinical Trials"},D5680C00002:{newDescription:"Join our chronic pain study exploring MEDI7352's impact on diabetic neuropathy. 12-week treatment, 6-week follow-up. Help us advance healthcare!",newTitle:"MEDI7352 Safety & Efficacy in Painful Diabetic Neuropathy"},D8480C00055:{newDescription:"Join our glioblastoma study: Compare cediranib, lomustine, or placebo to beat cancer. Help us find new treatments. AstraZeneca clinical trials.",newTitle:" Trials: Lomustine Chemotherapy Combined with Cediranib for Glioblastoma"},D5162C00052:{newDescription:"Join our trials to assess Osimertinib with Amivantamab's safety and efficacy in EGFR+ NSCLC. Help advance lung cancer treatment with AstraZeneca.",newTitle:"Safety and Efficacy of Osimertinib and Amivantamab in NSCLC"},D2600C00012:{newDescription:"Join our trial comparing AZD2423 with placebo for treating posttraumatic neuralgia. Discover its analgesic efficacy in just 28 days.",newTitle:"AZD2423 Study: Analgesic Efficacy on Posttraumatic Neuralgia Patients"},D9612L00066:{newDescription:"Compare Nexium & Protonix: Join post-IV therapy trial examining oral acid suppression. Help advance medicine with AstraZeneca clinical trials.",newTitle:"Comparing Nexium and Pantoprazole: Intragastric pH Profile Study"},D5890L00007:{newDescription:"Join AstraZeneca trial: Comparing inhalers' effects on asthma inflammation via allergen challenge in mild patients. Help advance research now!",newTitle:"Symbicort Classification Study: Allergic Patients with Mild Asthma"},D1449C00001:{newDescription:"Join AstraZeneca trials comparing fast titration of quetiapine to approved method. Assess efficacy of Seroquel SR/XR formulation. Sign up now!",newTitle:"Efficient Seroquel Titration for Schizophrenia: Taiwan Clinical Trials"},D7413C00001:{newDescription:"Join our clinical trial on eculizumab to treat aHUS in China! Discover efficacy and safety of this Phase 3b study. Help us make a difference!",newTitle:"Eculizumab for aHUS Treatment in Chinese Participants: Clinical Trial"},D1448C00004:{newDescription:"Join our trial evaluating the safety & efficacy of Seroquel XR (quetiapine fumarate SR
138) for Major Depressive Disorder. Limited spots available!",newTitle:"Seroquel SR + Antidepressant: Treating Major Depressive Disorder"},D5496C00005:{newDescription:"Join AZ clinical trial: Evaluating Verinurad + Allopurinol in Heart Failure with preserved Ejection Fraction for safety & efficacy. Act now!",newTitle:"Verinurad's Impact in Heart Failure with Preserved Ejection Fraction"},"5077%2F9059":{newDescription:"Join AstraZeneca trial! Assess efficacy of quetiapine/placebo, combined with SSRIs/clomipramine, for adult OCD. Help shape treatment options.",newTitle:"Quetiapine Augmentation for Severe OCD: Clinical Trial"},D5890L00008:{newDescription:"Join our trial comparing Symbicort's effectiveness in asthma. Compare flexible dose to standard treatment. Help advance medical knowledge!",newTitle:" Symbicort: Single Inhaler Therapy for Persistent Asthma"},"OM-EPA-006":{newDescription:"Join AstraZeneca's trial to evaluate Epanova\xae's effect on warfarin and compare EPA/DHA exposure to Lovaza\xae under low-fat meal conditions.",newTitle:"Lovaza Dosing Study: Effects on EPA & DHA | Trials"},D8330C00003:{newDescription:"Join AZ's HF & PH Study! AZD3427 Reduces PVR in 24 Weeks: Help fight heart failure & pulmonary hypertension. Join AstraZeneca trials now!",newTitle:" Clinical Trial: AZD3427 for Heart Failure & Pulmonary Hypertension (Group 2)"},D3250R00090:{newDescription:"Join AstraZeneca's BPAP study on benralizumab to describe characteristics, treatments, and outcomes in severe eosinophilic asthma patients.",newTitle:"UK Severe Asthma Study: Benralizumab Patient Access Program"},D5290C00001:{newDescription:"Join AstraZeneca trials! Assess safety & efficacy of long-lasting RSV antibody in healthy adults. Help combat respiratory syncytial virus.",newTitle:"MEDI8897 Study: Safety and Pharmacokinetics in Healthy Adults"},"NIS-CIN-DUM-2010%2F2":{newDescription:"Join our AstraZeneca trial, assessing sympathetic overactivity prevalence in newly diagnosed hypertension patients to improve treatments!",newTitle:"Sympathetic Overactivity in Primary Hypertension: Trial"},D5090C00021:{newDescription:"Join AstraZeneca: Study on New Drug Absorption, Safety, and Tolerability; Assessing Single, Multiple Doses & Interaction with Naproxen.",newTitle:"Double Blind Placebo Study: AZD1386 Safety & PK in Volunteers"},D4325C00007:{newDescription:"Join D4325C00007 study: Identify CKD patients, assess treatments, and shape future renal clinical advancements with AstraZeneca trials.",newTitle:"Study on Patients with Chronic Kidney Disease and Proteinuria"},D0810C00042:{newDescription:"Join AstraZeneca's Trial: Test Oral Olaparib on Advanced Cancer Patients with BRCA1/2 Mutation for Tumor Response & Effective Treatment",newTitle:"Olaparib Label Study: Efficacy & Safety in BRCA1/BRCA2 Mutations"},D9615C00014:{newDescription:"Join our Nexium trial: Compare oral vs. IV doses at 20mg to study GERD symptoms & acid output. Help advance research with AstraZeneca!",newTitle:"Nexium Study: Oral vs IV Esomeprazole in Randomized Crossover Trial"},"NIS-RKR-SYM-2007%2F1":{newDescription:"Join AstraZeneca's trial: Investigating Symbicort use in patients as maintenance and reliever therapy. Discover more about this study!",newTitle:"Symbicort SMART: Advanced Therapy for Clinical Trials"},"MI-CP145":{newDescription:"Join AstraZeneca trials: Assessing drug's safety, tolerability, and multiple doses in adult patients. Help advance medical research!",newTitle:"Safe & Tolerable Single-Dose Study: MEDI-545 | MedImmune.com Trials"},D1950C00008:{newDescription:"Join AstraZeneca trials: Discover AZD1446's profiles and food effect. Ensure safety with selected formulations in elderly volunteers.",newTitle:"Enhancing 's Bioavailability Study: Modified vs. Immediate Release Capsules"},D5084C00015:{newDescription:"Join AstraZeneca's trial: Evaluate fluvoxamine's impact on savolitinib levels in healthy males. Help us advance medical knowledge!",newTitle:"Effects of Fluvoxamine on S
138avolitinib Exposure: Study on Healthy Males"},D5890C00002:{newDescription:"Join AstraZeneca trial: Compare Symbicort & Seretide in asthma treatment. Prove efficacy & safety. Help improve medication.",newTitle:"Turbuhaler Comparison: Symbicort, Seretide & Terbutaline"},D589GC00002:{newDescription:"Bronchodilating effects of 3 formoterol dosages + budesonide: Join AstraZeneca trials to find out!",newTitle:"Formoterol vs. Foradil\xae Inhaler in Asthmatic Children (6-<12 yrs)"},D5100C00002:{newDescription:"Join our clinical trial to investigate the safety and tolerability of MEDI4920 in adult-onset rheumatoid arthritis, improving patient care.",newTitle:"MEDI4920 Phase 1b Study: Adult-Onset Rheumatoid Arthritis Trials Nearby"},"CIN-107-123":{newDescription:"Assess CIN-107's efficacy and safety in treating uncontrolled hypertension and CKD; join our trial to make a difference in transforming hypertension management.",newTitle:"Effective Hypertension & CKD Treatment with CIN-107: Clinical Trial"},D525AL00001:{newDescription:"Join this study is to confirm the safety profile for long term treatment in children aged 5 years and <15 years on bronchial asthma in daily clinical usage.",newTitle:"Pulmicort Clinical Trials: Investigating Specific Experiences with Turbuhaler"},D5890L00004:{newDescription:"Compare Symbicort with Best Conventional Practice for persistent asthma. Join AstraZeneca's trial to revolutionize asthma treatment.",newTitle:"SOLO-Symbicort Asthma Study | Treatment for Adolescents & Adults"},"ALXN1720-MG-301":{newDescription:"Join our trial on ALXN1720, a study evaluating its safety and effectiveness in treating generalized MG (gMG) in adults with autoantibodies against AChR.",newTitle:"ALXN1720: Safety and Efficacy for Myasthenia Gravis - Trials"},D8535C00001:{newDescription:"Join our open-label trial comparing camizestrant to standard endocrine therapy for ER+/HER2- breast cancer patients with intermediate-high or high risk for recurrence.",newTitle:"Camizestrant Study: Adjuvant Endocrine Therapy for ER+/HER2- Early Breast Cancer"},D4320C00006:{newDescription:"Join AstraZeneca's trial to test ZD4054's (Zibotentan) effectiveness in treating prostate cancer and bone metastasis, while ensuring safety.",newTitle:"Zibotentan for Prostate Cancer & Bone Metastases: Clinical Trial"},D419CR00030:{newDescription:"Join AstraZeneca's clinical trial evaluating STRIDE as first-line therapy for advanced unresectable HCC, assessing safety and efficacy. ",newTitle:"Durvalumab HCC Trial: First-Line Treatment for Advanced Hepatocellular Carcinoma"},D9077C00001:{newDescription:"Assessing safety & efficacy of Durvalumab combos in early-stage lung cancer; Join AstraZeneca's trial for innovative treatment options - limited spots available!",newTitle:"Neoadjuvant & Adjuvant Treatment with AZD0171"},D5741C00002:{newDescription:"Join our study comparing roxadustat and rHuEPO on iron absorption in Stage 4 and Stage 5 CKD anemia patients - contribute to advancing medical knowledge!",newTitle:"Comparing Roxadustat and RHuEPO: Oral Iron Absorption in Chinese CKD Patients"},"4522IL%2F0095":{newTitle:"Gemfibrozil Dose Trial: Effect on Rosuvastatin Pharmacokinetics"},"9238IL%2F0020":{newTitle:"Faslodex vs. Arimidex: Breast Cancer Trial for Postmenopausal Women"},"9393IL%2F0027":{newTitle:"Multicentre Study: ZOLADEX Effect in Endometriosis - 9393IL/0026 Follow-on"},"9393IL%2F0028":{newTitle:"Goserelin Acetate Clinical Trial for Prostate Cancer: "},ACO5:{newTitle:"CMF vs ZOLADEX + Tamoxifen in Patients & Breast Cancer"},"BY217%2FM2-017":{newTitle:" Study: Montelukast 500 10mg vs Roflumilast - Asthma Comparison"},D1444C00003:{newTitle:"Comparing Quetiapine Fumarate 300 mg for Schizophrenic Adults"},D9615L00005:{newTitle:"Efficacy and Safety of Double Blind Double Dummy Esomeprazole Trial"},"NIS-CKR-CRE-2007%2F8":{newTitle:"Crestor Diabetes Trial: Efficacy of Rosuvastatin for Korean Patients"},"SH-QBE-0083":{newTitle:"Efficacy Comparison: Esomeprazole Magnesium 40 in Erosive Esophagitis"}};var ea=a(6570),ei=a(7328),es=a.n(ei),el=!0;let en=({header:e,footer:t,staticData:a,study:i,study_id:d})=>{var u;let m,p;i=i.value;let{parsedData:h}=(0,o.A)(Q,ee,(u=(0,r.getKeystoneWebsiteId)(),{where:{id:{equals:u},publishStatus:{in:m=(0,r.getWebsiteStatuses)()}},take:1,astrazenecaPageTrialDetailsWhere2:{publishStatus:{in:m}},armsLabelsWhere2:{publishStatus:{in:m}},contactLabelsWhere2:{publishStatus:{in:m}},detailsLabelsWhere2:{publishStatus:{in:m}},locationSortByStatusDropdownWhere2:{publishStatus:{in:m}},publicationsLinkWhere2:{publishStatus:{in:m}},resultsTabWhere2:{publishStatus:{in:m}}})),{parsedData:f}=(0,o.A)(l.zS,l.dn,(0,l.BI)((0,r.getKeystoneWebsiteId)())),{parsedData:b}=(0,o.A)(n.zT,n.pC,(0,n.DU)((0,r.getKeystoneWebsiteId)())),x=h||a,y=f||t;return i&&i.protocol_form||console.warn("\uD83D\uDEA8 Study or protocol_form is missing",i),y&&y.links||console.warn("\uD83D\uDEA8 Footer data or links are missing",y),(0,s.jsxs)(s.Fragment,{children:[(0,s.jsx)(es(),{children:(0,s.jsx)(ea.e,{path:`/study/${d}/`})}
138),(0,s.jsx)("div",{id:"study-details-page",children:(0,s.jsx)(c.P,{headerContent:b||e,footerContent:y,lightTheme:!0,seo:{title:`${i&&i.protocol_form?i.protocol_form.brief_title:"Study Details Page"}`,description:et[p=i.protocol_form.org_study_id]&&et[p].newDescription?et[p].newDescription:i&&i.protocol_form?i.protocol_form.brief_summary:"Study Details Page"},canonicalUrl:i&&i.protocol_form?`/study/${d}`:"",children:(0,s.jsxs)("div",{className:"padding-header",children:[x?.studyDetailsLabels&&(0,s.jsx)(w,{pageData:x.studyDetailsLabels,returnBtn:!0}),x&&x.heroLabels&&(0,s.jsx)(v,{study:i?.protocol_form,labels:x.heroLabels}),x&&(0,s.jsx)(K,{study:i?.protocol_form,labels:x})]})})})]})}},8696:(e,t,a)=>{"use strict";a.d(t,{d:()=>o});var i=a(7876);a(4232);var s=a(1238),l=a.n(s),n=a(2051),r=a(1025);let o=({onChange:e,totalItems:t,itemsPerPage:a,page:s,className:o})=>{let{width:c}=(0,r.A)();return(0,i.jsx)(l(),{previousLabel:(0,i.jsx)(n.FaAngleLeft,{}),forcePage:s,nextLabel:(0,i.jsx)(n.FaAngleRight,{}),breakLabel:"...",pageCount:Math.ceil(t/a),marginPagesDisplayed:c&&c<768?2:3,pageRangeDisplayed:c&&c<768?1:3,onPageChange:e,containerClassName:`pagination ${o}`,activeClassName:"active"})}},8847:(e,t,a)=>{e.exports=a(705)}},e=>{e.O(0,[956,371,826,238,113,636,593,792],()=>e(e.s=1072)),_N_E=e.O()}]);
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.